Agnico Eagle Mines Ltd vs Citius Pharmaceuticals Inc — how do they compare? Agnico Eagle Mines Ltd trades at $184.84 (market cap $92.01B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Agnico Eagle Mines Ltd is far larger — about 4598.2× Citius Pharmaceuticals Inc's market cap, and Agnico Eagle Mines Ltd pays a 0.99% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEM | CTXR | |
|---|---|---|
Market Cap | $92.01B | $20.01M |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $1.82 |
52-Week Low | $130.23 | $0.48 |
Enterprise Value | $88.85B | $16.23M |
Dividend Yield | 0.99% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Trailing returns across standard periods
Latest headlines on both assets
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →